Welcome to our dedicated page for Akoya BioSciences news (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya BioSciences stock.
Akoya BioSciences, Inc. (Nasdaq: AKYA) is a leading life sciences technology company pioneering spatial biology solutions that transform discovery, clinical research, and diagnostics. Akoya is committed to advancing the science of imaging with its comprehensive platforms, including PhenoCycler® and PhenoImager®, that perform deep proteomic profiling and spatial phenotyping. These cutting-edge platforms enable researchers to analyze tissue samples with high precision, providing insights into cellular interactions and disease mechanisms.
In 2024, Akoya announced preliminary unaudited revenue for Q4 2023 between $25.5 million and $26.5 million, marking a significant increase from Q4 2022. For the fiscal year 2023, revenues are expected to reach between $95.6 million and $96.6 million.
Akoya's portfolio includes innovative products like PhenoCode™ Panels, PhenoCycler®, and PhenoImager® HT, which support high-throughput and high-parameter tissue analysis. Notably, the company has recently partnered with Thermo Fisher Scientific to enhance its spatial multiomic workflow by integrating ViewRNA technology.
The company's technology has attracted significant attention in the scientific community, with its systems cited in over 1,300 publications as of March 2024. Akoya has also formed strategic partnerships and collaborations, including with the Queensland Spatial Biology Centre and organizations like BostonGene and NeraCare, enhancing the application of its platforms in various fields of research and clinical diagnostics.
Financially, Akoya aims for substantial revenue growth in 2024 with projections exceeding 20%, supported by its robust balance sheet and strategic initiatives like the new Manufacturing Center of Excellence in Marlborough, MA. This facility is expected to streamline operations, improve supply chain efficiency, and meet the growing demand for spatial biology solutions.
If you're a scientist or software engineer passionate about revolutionizing imaging science, Akoya BioSciences offers an exciting environment for innovation. For more information, contact Akoya at info@akoyabio.com.
Akoya Biosciences, Inc. (NASDAQ: AKYA) has appointed Dr. Myla Lai-Goldman to its board of directors. With extensive experience in the diagnostics industry, Dr. Lai-Goldman aims to enhance Akoya's efforts in spatial biology, which has potential applications in life sciences. CEO Brian McKelligon expressed excitement about her joining the team as the company enters a new growth phase. Dr. Lai-Goldman's background includes key roles at LabCorp and co-founding GeneCentric Therapeutics, positioning her to drive Akoya's mission of advancing patient care through innovative solutions.
Akoya Biosciences, known as The Spatial Biology Company®, announced its virtual participation in the Morgan Stanley 19th Annual Global Healthcare Conference. The event will feature a fireside chat with CEO Brian McKelligon and CFO Joe Driscoll on September 13, 2021, at 5:00 p.m. ET. A live webcast will be available on Akoya's website for 90 days following the event. Akoya specializes in spatial phenotyping and offers platforms like CODEX® and Phenoptics™ to enhance research in biology and human health.
Akoya Biosciences (Nasdaq: AKYA) reported strong financial results for Q2 2021, achieving total revenue of $13.1 million, a 53% increase from $8.6 million in Q2 2020. Notable growth in reagent sales reached $4.3 million, up from $1.5 million year-over-year. Gross profit was $8.1 million, with a gross profit margin of 62.2%. The company announced significant strategic initiatives, including a partnership with AstraZeneca and the launch of the Imaging Innovators Network, further solidifying its role in spatial biology.
Akoya Biosciences (Nasdaq: AKYA) will participate virtually in the Canaccord 41st Annual Growth Conference on August 11, 2021, at 2:00 p.m. ET. CEO Brian McKelligon is scheduled to present, providing insights into the company’s innovative spatial biology technologies that aid in understanding biology and health. Akoya specializes in single-cell imaging solutions, including the CODEX® and Phenoptics™ platforms, enhancing research in disease progression and treatment response. For inquiries, contact Canaccord sales representatives.
Akoya Biosciences, Inc. (Nasdaq: AKYA) will announce its financial results for Q2 2021 on August 10, 2021, after market close. The company will hold a conference call at 5:00 p.m. ET to discuss the results. Investors can join the call by dialing (833) 562-0146 for domestic or (661) 567-1226 for international participants, using Conference ID: 8057237. The webcast will also be available on Akoya's investor relations website.
Akoya specializes in spatial biology, offering solutions like CODEX® and Phenoptics™ to enhance cellular research.
Akoya Biosciences announced results from a multi-site study demonstrating the standardization of an automated spatial biology workflow using their Phenoptics™ multiplex immunofluorescence (mIF) platform for clinical research. The MITRE study, involving top institutions like Johns Hopkins and MD Anderson, validated the workflow for characterizing PD-1/PD-L1 immune checkpoint signaling in tumors. The findings indicate that the automated mIF method could enhance clinical trial outcomes and support predictive biomarker development for immunotherapies.
Akoya Biosciences (Nasdaq: AKYA) has announced new partnerships with Nikon, CrestOptics, and Andor to enhance its CODEX® solution for single-cell imaging. These collaborations aim to improve spatial biology applications and streamline user experiences. The partnerships will allow for faster acquisition speeds and better resolution in imaging. Researchers are invited to join the I2 Network for developing new applications, with applications open until July 9. CEO Brian McKelligon highlighted the commitment to broaden access to innovations in spatial biology.
Akoya Biosciences (NASDAQ: AKYA) announced the appointment of Scott Mendel to its Board of Directors. Mendel, a seasoned diagnostics industry leader, previously served as CEO of GenMark Diagnostics, which was acquired by Roche for $1.8 billion. His expertise in transforming innovative technologies into clinical solutions aligns with Akoya's mission to enhance biomarker discovery through spatial biology platforms. CEO Brian McKelligon expressed confidence in Mendel’s ability to drive insights as the company advances its strategic goals.
Akoya Biosciences (Nasdaq: AKYA) announced that its CODEX® solution will be part of the Chan Zuckerberg Initiative (CZI) grantees' toolkit, enhancing biological research capabilities with single-cell, whole-tissue imaging. This collaboration aims to support over 350 labs in the CZI network, focusing on spatial phenotyping to better understand cellular interactions and disease progression. The company’s CEO expressed enthusiasm for this addition, emphasizing its potential for breakthrough discoveries in health research.
Akoya Biosciences (NASDAQ: AKYA) announced collaboration with Johns Hopkins University (JHU) on AstroPath, a platform for predicting immunotherapy responses in advanced melanoma. Utilizing Akoya’s Phenoptics solution, researchers identified a composite spatial phenotypic signature that predicts response to anti-PD-1 therapy with an impressive area under the curve (AUC) of 0.91. This study, published in Science, highlights the potential of spatial biomarkers for enhancing immunotherapy precision and could impact other cancer types. The research underscores a groundbreaking approach to biomarker discovery.
FAQ
What is the current stock price of Akoya BioSciences (AKYA)?
What is the market cap of Akoya BioSciences (AKYA)?
What does Akoya BioSciences, Inc. do?
What are Akoya's core products?
How did Akoya perform financially in 2023?
Who are some of Akoya's key partners?
What recent achievements has Akoya announced?
How many publications have cited Akoya's technology?
What is Akoya's financial outlook for 2024?
What is the significance of the new Manufacturing Center of Excellence?
Who should consider working at Akoya BioSciences?
How can one contact Akoya BioSciences for more information?
